• Net Sales: Reached a record CHF6.8 billion, supported by 7.5% organic growth.
• Adjusted Operating Income: CHF140 million, translating into a 15.3% margin on sales, 60 basis points above 2023.
• Earnings Per Share (EPS): CHF3.10, a growth of 3.3% despite restructuring expenses.
• Free Cash Flow: CHF748 million, up by 24% compared to 2023.
• Organic Sales Growth: 7.5%, equivalent to CHF494 million.
• Forex Impact: Negative translation impact of 4.8% on sales.
• Operating Income Margin: Improved by 60 basis points to 15.3%.
• Return on Invested Capital (ROIC): 24%, 2 percentage points higher than 2023.
• Net Debt Leverage: Improved from 2 times in 2023 to 1.8 times in 2024.
• Dividend Proposal: CHF3.20 per share, with an option for cash or shares.
• Acquisitions: 14 bolt-on acquisitions in 2024, with 3 more announced in 2025.
• Incremental Sales from Sustainability: CHF100 million recorded.
• Organic Sales Growth by Region: LATAM expanded by more than 17%, Eastern Europe, Middle East, and Africa grew by 14.1%.
• Operational Efficiency Savings: CHF50 million savings in 2024, with a target of CHF150 million by end of 2025.

• Warning! GuruFocus has detected 6 Warning Sign with SGSOF.

Release Date: February 11, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• SGS AG (SGSOF) achieved record sales of CHF6.8 billion in 2024, supported by strong organic growth of 7.5%.
• The company executed 14 bolt-on acquisitions in 2024, enhancing its portfolio and bringing complementary expertise.
• SGS AG (SGSOF) reported an outstanding free cash flow of CHF748 million, up by 24% compared to 2023.
• The company maintained a strong ESG profile, being ranked as the first professional services company in the Dow Jones sustainability indices.
• SGS AG (SGSOF) achieved a 24% return on invested capital, driven by increased profitability and value-accretive acquisitions.

Negative Points

• The company faced a negative forex translation impact of 4.8% on sales and 7.1% on adjusted operating income.
• There was a slowdown in training and unfavorable comparables in consulting, impacting business assurance growth.
• SGS AG (SGSOF) incurred CHF82 million in restructuring costs for the execution of its linear operating model savings plan.
• The company experienced a slowdown in the European agriculture sector due to the new crop season.
• Margins in the connectivity and products division were slightly down, indicating tension between reinvestment and operating leverage.

Q & A Highlights

Q: With the incoming US administration's stance against sustainability and ESG, do you see any risk to growth in your business, particularly in business assurance? Also, regarding M&A, could we see you doing a larger deal beyond the 1% to 2% from bolt-ons? A: We see opportunities in the US, especially with increased PFAS testing. Environmental growth was 30% in the US in 2024. Regarding M&A, we are open to larger deals if they align with Strategy 27 and provide shareholder returns. The market is fragmented, and we will evaluate opportunities carefully.

Q: Why did you settle on a 30 basis points margin guidance despite strong momentum? Is a larger deal necessary for higher organic growth? A: The margin guidance is conservative due to potential macroeconomic or political headwinds. We will evaluate all M&A opportunities, but any deal must deliver shareholder returns and align with our strategy. Scale is important, and we aim to lead in innovation and service offerings.

Q: With deregulation trends in the US and Europe, do you see this as a headwind? Also, how sustainable is the free cash flow conversion improvement? A: Deregulation may lead to stricter state-level regulations, which could benefit us. The consumer demand for sustainability remains strong. The free cash flow improvement is sustainable due to a focus on working capital and disciplined CapEx aligned with growth priorities.

Q: Can you explain the margin investments and the impact of non-renewed contracts on growth? A: Margin investments include expanding teams in growth areas like medical devices. The non-renewed contracts accounted for about 0.5% of growth. The run rate for cost savings will be reached by the end of 2025.

Q: How do you evaluate risks in larger M&A deals, considering potential revenue dis-synergies and portfolio overlap? A: We thoroughly study all aspects of potential deals, including integration risks and synergies. We aim to play an active role in industry consolidation while ensuring any deal aligns with our strategic goals and delivers value.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.